Auditory function in adrenomyeloneuropathy

Joseph P Pillion1, Hugo W Moser, Gerald V Raymond

  • 1Kennedy Krieger Institute, United States. pillion@kennedykrieger.org

Insights

Auditory brainstem responses (ABR) reveal significant hearing pathway abnormalities in adrenomyeloneuropathy (AMN) patients, even when individuals report no hearing difficulties. Early ABR wave components are most frequently affected.

Area of Science:

  • Neuroscience
  • Audiology
  • Genetics

Background:

  • Adrenomyeloneuropathy (AMN) is a rare genetic disorder affecting the nervous system and adrenal glands.
  • Hearing impairment can be a symptom of AMN, but its audiological profile is not fully understood.
  • Auditory pathway integrity is crucial for communication and quality of life.

Purpose of the Study:

  • To investigate auditory pathway function in patients with adrenomyeloneuropathy (AMN).
  • To characterize auditory brainstem responses (ABR), acoustic reflexes, and masking level differences (MLD) in AMN.
  • To correlate audiological findings with the clinical presentation of AMN.

Main Methods:

  • Auditory brainstem responses (ABR) were recorded in 29 AMN patients.
  • Ipsilateral and contralateral acoustic reflexes were assessed.
  • Masking level difference for speech (MLD) was measured.
  • ABR wave latencies and reflex parameters were analyzed.

Main Results:

  • All patients showed abnormalities in ABR components, with Waves V and III most affected.
  • Interpeak latency intervals (I-III, III-V, I-V) were abnormal in a majority of male and female AMN patients.
  • Contralateral acoustic reflexes were abnormal in ~50% of ears, and ipsilateral reflexes in 25%.
  • MLDs were significantly reduced in 72% of patients.
  • Early ABR components (Waves III and I) were the initial sites of impairment.
  • Word recognition in quiet was largely unaffected.
  • Patients often denied significant hearing difficulties despite objective ABR abnormalities.

Conclusions:

  • The auditory pathway, particularly early ABR components, is frequently affected in AMN.
  • Objective audiological testing reveals significant hearing pathway dysfunction in AMN patients, often unperceived by the patients.
  • These findings highlight the importance of comprehensive audiological assessment in AMN management.

Related Concept Videos

Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Diabetic Neuropathy01:22

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...